Literature DB >> 11888078

Carisoprodol: an unrecognized drug of abuse.

David N Bailey1, John R Briggs.   

Abstract

During a 6-month monitoring period, carisoprodol was detected in the urine specimens of 19 patients for whom drug screening had been ordered for purposes of patient care. The clinical history suggested that in 7 cases the drug was abused or implicated in a suicide attempt or gesture. In another 7 cases, the drug was used primarily for medical purposes, and in 5 cases the reason for use could not be determined. One patient ingested homemade tablets that were found to contain carisoprodol. In an additional case, the drug was detected in breast milk. Physical findings, clinical history, and treatment are described, and the profile of a typical carisoprodol user is discussed. It seems that carisoprodol has become an unrecognized drug of abuse, at least in our community. This drug and its metabolite, meprobamate, should be included in comprehensive drug screening.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888078     DOI: 10.1309/4KTM-CY6N-572P-7ERD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003.

Authors:  Gudrun Høiseth; Jørgen G Bramness; Asbjørg S Christophersen; Jørg Mørland
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

2.  Carisoprodol pharmacokinetics and distribution in the nucleus accumbens correlates with behavioral effects in rats independent from its metabolism to meprobamate.

Authors:  Theresa M Carbonaro; Vien Nguyen; Michael J Forster; Michael B Gatch; Laszlo Prokai
Journal:  Neuropharmacology       Date:  2020-05-29       Impact factor: 5.250

3.  Carisoprodol tolerance and precipitated withdrawal.

Authors:  Michael B Gatch; Jacques D Nguyen; Theresa Carbonaro; Michael J Forster
Journal:  Drug Alcohol Depend       Date:  2011-11-04       Impact factor: 4.492

4.  CYP2C19 genetics in fatal carisoprodol intoxications.

Authors:  Gudrun Høiseth; Umair Majid; Jørg Mørland; Jørgen G Bramness; Espen Molden
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

5.  The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Margaretha Gulliksen; Harald Breilid; Vidar M Steen; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2005-07-15       Impact factor: 2.953

6.  Carisoprodol use and abuse in Norway: a pharmacoepidemiological study.

Authors:  Jørgen G Bramness; Kari Furu; Anders Engeland; Svetlana Skurtveit
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

7.  Abuse Potential of Soma: the GABA(A) Receptor as a Target.

Authors:  Lorie A Gonzalez; Michael B Gatch; Michael J Forster; Glenn H Dillon
Journal:  Mol Cell Pharmacol       Date:  2009-01-01

8.  Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma.

Authors:  Gunchan Paul; Gautam L Parshotam; Rajneesh Garg
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jul-Sep

9.  Carisoprodol abuse in Texas, 1998-2003.

Authors:  Mathias B Forrester
Journal:  J Med Toxicol       Date:  2006-03

10.  Single and Multiple Dose PK-PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers.

Authors:  Aitana Calvo; Saioa Alonso; Esther Prieto; Ana Ascaso-Del-Rio; Jordi Ortuño; Nieves Fernandez; Antonio Portolés
Journal:  J Clin Med       Date:  2022-02-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.